(397) Polymeric nanoparticles delivering bevacizumab and avoiding hyperglycolysis in glioblastoma therapy

Aberrant neovascularization and enhanced VEGF expression make anti-angiogenic bevacizumab therapy a promising approach to slow glioblastoma progression. However, despite symptom relief, glioblastoma patients do not exhibit a durable response to bevacizumab monotherapy, and this treatment fails to provide a survival benefit [1]. Building on findings that bevacizumab fails due to (i) low brain penetration and (ii) hyperglycolysis activation on tumor cells, we developed dual-drug polymeric nanoparticles delivering bevacizumab and glycolysis inhibitor dichloroacetate: BDNP [2,3].